famotidine has been researched along with Heart Failure in 9 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twelve patients with stable congestive heart failure and left ventricular dysfunction were enrolled in a double-blind, randomized crossover trial of famotidine, cimetidine and placebo to determine whether histamine type 2 (H2) antagonists adversely affect left ventricular systolic performance." | 9.07 | Effects of histamine type 2-receptor antagonists cimetidine and famotidine on left ventricular systolic function in chronic congestive heart failure. ( Jarboe, LA; Lee, RT; Solomon, SD; Wolfe, MM; Wolff, S, 1993) |
| "In a randomized, placebo-controlled, double-blind study, 12 patients with congestive heart failure (New York Heart Association class II) were successively treated for 1 week each with placebo, 40 mg famotidine, and 1000 mg quinidine." | 9.07 | Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. ( Halabi, A; Hinrichsen, H; Kirch, W, 1992) |
| "Histamine has a positive inotropic effect on ventricular myocardium and stimulation of histamine H₂ receptors increases the intracellular cAMP level via Gs protein, as dose stimulation of β-adrenergic receptors, and worsens heart failure." | 7.76 | A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade. ( Asakura, M; Asanuma, H; Fujita, M; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2010) |
| " However, the association of famotidine and acquired long QT syndrome has rarely been reported." | 7.72 | Famotidine and long QT syndrome. ( Hongo, RH; Kayser, SR; Lee, KW; Scheinman, MM; Tseng, ZH, 2004) |
| "Twelve patients with stable congestive heart failure and left ventricular dysfunction were enrolled in a double-blind, randomized crossover trial of famotidine, cimetidine and placebo to determine whether histamine type 2 (H2) antagonists adversely affect left ventricular systolic performance." | 5.07 | Effects of histamine type 2-receptor antagonists cimetidine and famotidine on left ventricular systolic function in chronic congestive heart failure. ( Jarboe, LA; Lee, RT; Solomon, SD; Wolfe, MM; Wolff, S, 1993) |
| "In a randomized, placebo-controlled, double-blind, crossover comparison, 12 patients with congestive heart failure (New York Heart Association class II) and dyspeptic complaints were treated orally for 1 week each with placebo, 40 mg omeprazole daily, and 40 mg famotidine daily." | 5.07 | Cardiovascular effects of omeprazole and famotidine. ( Halabi, A; Kirch, W, 1992) |
| "In a randomized, placebo-controlled, double-blind study, 12 patients with congestive heart failure (New York Heart Association class II) were successively treated for 1 week each with placebo, 40 mg famotidine, and 1000 mg quinidine." | 5.07 | Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. ( Halabi, A; Hinrichsen, H; Kirch, W, 1992) |
| "Histamine has a positive inotropic effect on ventricular myocardium and stimulation of histamine H₂ receptors increases the intracellular cAMP level via Gs protein, as dose stimulation of β-adrenergic receptors, and worsens heart failure." | 3.76 | A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade. ( Asakura, M; Asanuma, H; Fujita, M; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2010) |
| " However, the association of famotidine and acquired long QT syndrome has rarely been reported." | 3.72 | Famotidine and long QT syndrome. ( Hongo, RH; Kayser, SR; Lee, KW; Scheinman, MM; Tseng, ZH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, YH | 1 |
| Cai, WK | 1 |
| Yin, SJ | 1 |
| Wang, P | 1 |
| Li, ZR | 1 |
| Yang, Q | 1 |
| Zhou, T | 1 |
| Meng, R | 1 |
| Yang, M | 1 |
| Guo, Y | 1 |
| He, GH | 1 |
| Takahama, H | 1 |
| Asanuma, H | 2 |
| Sanada, S | 2 |
| Fujita, M | 2 |
| Sasaki, H | 1 |
| Wakeno, M | 2 |
| Kim, J | 2 |
| Asakura, M | 2 |
| Takashima, S | 2 |
| Minamino, T | 2 |
| Komamura, K | 2 |
| Sugimachi, M | 1 |
| Kitakaze, M | 2 |
| Lee, KW | 1 |
| Kayser, SR | 1 |
| Hongo, RH | 1 |
| Tseng, ZH | 1 |
| Scheinman, MM | 1 |
| Ogai, A | 1 |
| Hirata, A | 1 |
| Tsukamoto, O | 1 |
| Shinozaki, Y | 1 |
| Myoishi, M | 1 |
| Tomoike, H | 1 |
| Kolck, UW | 1 |
| Alfter, K | 1 |
| Homann, J | 1 |
| von Kügelgen, I | 1 |
| Molderings, GJ | 1 |
| Solomon, SD | 1 |
| Wolff, S | 1 |
| Jarboe, LA | 1 |
| Wolfe, MM | 1 |
| Lee, RT | 1 |
| Halabi, A | 2 |
| Kirch, W | 2 |
| Hinrichsen, H | 1 |
| Berlin, RG | 1 |
3 trials available for famotidine and Heart Failure
| Article | Year |
|---|---|
Effects of histamine type 2-receptor antagonists cimetidine and famotidine on left ventricular systolic function in chronic congestive heart failure.
Topics: Aged; Analysis of Variance; Chronic Disease; Cimetidine; Double-Blind Method; Echocardiography; Famo | 1993 |
Cardiovascular effects of omeprazole and famotidine.
Topics: Aged; Cardiac Output; Double-Blind Method; Dyspepsia; Famotidine; Female; Heart Failure; Hemodynamic | 1992 |
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure.
Topics: Cardiac Output; Double-Blind Method; Famotidine; Female; Heart Failure; Hemodynamics; Humans; Male; | 1992 |
6 other studies available for famotidine and Heart Failure
| Article | Year |
|---|---|
Histamine H2 receptor antagonist exposure was related to decreased all-cause mortality in critical ill patients with heart failure: a cohort study.
Topics: Cohort Studies; Critical Illness; Famotidine; Heart Failure; Histamine H2 Antagonists; Humans; Ranit | 2022 |
A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiac Catheterization; Cardiac Pacing, Artificia | 2010 |
Famotidine and long QT syndrome.
Topics: Aged; Aged, 80 and over; Diagnosis, Differential; Electrocardiography; Famotidine; Heart Failure; Hi | 2004 |
Blockade of histamine H2 receptors protects the heart against ischemia and reperfusion injury in dogs.
Topics: Animals; Dogs; Famotidine; Heart Failure; Hemodynamics; Histamine H2 Antagonists; Myocardial Ischemi | 2006 |
Cardiac mast cells: implications for heart failure.
Topics: Chronic Disease; Famotidine; Female; Heart Failure; Humans; Male; Mast Cells; Mastocytosis, Systemic | 2007 |
Famotidine does not have a negative inotropic effect.
Topics: Animals; Depression, Chemical; Dogs; Famotidine; Heart Failure; Humans; Myocardial Contraction; Rats | 1987 |